Arthur H. Bell, D.O.; Decision and Order, 50035-50041 [2015-20353]
Download as PDF
Federal Register / Vol. 80, No. 159 / Tuesday, August 18, 2015 / Notices
therefore not entitled to maintain her
DEA registration. See 21 U.S.C. 802(21),
823(f), and 824(a)(3). Accordingly, I will
order that her registration be revoked.
Order
Pursuant to the authority vested in me
by 21 U.S.C. 824(a), as well as 28 CFR
0.100(b), I order that DEA Certificate of
Registration MH2194176 issued to
Devra A. Hamilton, A.P.N., be, and it
hereby is, revoked. I further order that
any pending application of Devra A.
Hamilton, A.P.N., to renew or modify
her registration, be, and it hereby is,
denied. This Order is effective
September 17, 2015.
Administrator of the DEA Office of
Diversion Control (‘‘Deputy Assistant
Administrator’’) pursuant to section 7 of
28 CFR part 0, appendix to subpart R.
In accordance with 21 CFR
1301.33(a), this is notice that on March
30, 2015, IRIX Manufacturing, Inc., 309
Delaware Street, Building 1106,
Greenville, South Carolina 29605
applied to be registered as a bulk
manufacturer of the following basic
classes of controlled substances:
Controlled Substance
Marihuana (7360) .........................
Tetrahydrocannabinols (7370) .....
Schedule
I
I
The company plans to manufacture
the above-listed controlled substances
as Active Pharmaceutical Ingredient
(API) for clinical trials.
Dated: August 10, 2015.
Chuck Rosenberg,
Acting Administrator.
[FR Doc. 2015–20348 Filed 8–17–15; 8:45 am]
Dated: August 10, 2015.
Joseph T. Rannazzisi,
Deputy Assistant Administrator.
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
[FR Doc. 2015–20285 Filed 8–17–15; 8:45 am]
BILLING CODE 4410–09–P
Drug Enforcement Administration
[Docket No. DEA–392]
DEPARTMENT OF JUSTICE
Bulk Manufacturer of Controlled
Substances Application: IRIX
Manufacturing, Inc.
ACTION:
Arthur H. Bell, D.O.; Decision and
Order
Notice of application.
Registered bulk manufacturers of
the affected basic classes, and
applicants therefore, may file written
comments on or objections to the
issuance of the proposed registration in
accordance with 21 CFR 1301.33(a) on
or before October 19, 2015.
ADDRESSES: Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/ODXL, 8701
Morrissette Drive, Springfield, Virginia
22152. Request for hearings should be
sent to: Drug Enforcement
Administration, Attention: Hearing
Clerk/LJ, 8701 Morrissette Drive,
Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION: The
Attorney General has delegated his
authority under the Controlled
Substances Act to the Administrator of
the Drug Enforcement Administration
(DEA), 28 CFR 0.100(b). Authority to
exercise all necessary functions with
respect to the promulgation and
implementation of 21 CFR part 1301,
incident to the registration of
manufacturers, distributors, dispensers,
importers, and exporters of controlled
substances (other than final orders in
connection with suspension, denial, or
revocation of registration) has been
redelegated to the Deputy Assistant
DATES:
asabaliauskas on DSK5VPTVN1PROD with NOTICES
Drug Enforcement Administration
VerDate Sep<11>2014
17:02 Aug 17, 2015
Jkt 235001
On July 15, 2014, the Deputy
Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration, issued an Order to
Show Cause to Arthur H. Bell, D.O.
(Respondent), of Covington, Kentucky.
GX 1, at 1. The Show Cause Order
proposed the denial of Respondent’s
application for a DEA Certificate of
Registration as a practitioner on
multiple grounds, including that he had
materially falsified his application for a
registration, as well as that he had
committed acts which render his
registration inconsistent with the public
interest. Id. at 1–2 (citing 21 U.S.C.
823(f) and 824(a)(1)).
As for the material falsification
allegation, the Show Cause Order
alleged that on November 9, 2011,
Respondent had voluntarily surrendered
his previous DEA Registration. Id. The
Order then alleged that on March 14,
2013, Respondent applied for a new
DEA registration, but materially falsified
the application when he ‘‘answered ‘no’
to question which asked, ‘[h]as the
Respondent ever surrendered (for cause)
or had a federal controlled substance
registration revoked, suspended,
restricted or denied, or is any such
action pending?’’’ Id.
As for the allegations that Respondent
had committed acts which render his
PO 00000
Frm 00051
Fmt 4703
Sfmt 4703
50035
registration inconsistent with the public
interest, the Show Cause Order alleged
that Respondent violated federal law by
issuing controlled substance
prescriptions when he ‘‘no longer
possessed a DEA registration.’’ Id. at 2
(citing 21 CFR 1306.03(a)). More
specifically, the Order alleged that on
May 5, 2012, Respondent had issued a
prescription for 60 tablets of Lyrica 75
mg, a schedule V controlled substance,
and on September 12, 2012, Respondent
had issued a prescription for Zutripro
120 ml, a schedule III controlled
substance. Id.
The Show Cause Order also alleged
that from July 11, 2011 through
November 4, 2011, Respondent
‘‘dispensed controlled substances on
behalf of Care Plus Medical Group
(CPMG), a purported pain management
clinic formerly located in Creve Coeur,
Missouri, [which] was owned by Scott
Whitney.’’ Id. The Order alleged that
prior to beginning his employment with
CPMG, Respondent arranged with
Whitney to order schedule II controlled
substances under his previous
registration and that ‘‘[t]o that end, . . .
Whitney sent 20 DEA 222 forms to
[Respondent’s] residence, and asked
that [he] pre-sign them so that
controlled substances could be ordered
on behalf of CPMG.’’ Id. The Order then
alleged that Respondent ‘‘pre-signed the
forms, dated them . . . and mailed them
to . . . Whitney . . . [who] then used one
. . . to place orders for oxycodone 30 mg
and oxycodone 10/325 mg.’’ Id. The
Order alleged that this violated federal
law because it ‘‘authoriz[ed] . . .
Whitney to place an order for controlled
substances under [Respondent’s]
previous . . . registration without
executing a power of attorney for . . .
Whitney.’’ Id. (citing 21 CFR
1303.05(a)).
Next, the Show Cause Order alleged
that on October 28, 2013, Respondent
falsified his application for his Ohio
medical license, when he failed to
disclose that he had previously
surrendered his DEA registration. Id. at
1–2. The Order further alleged that this
‘‘conduct evidences a lack of candor to
Ohio licensing authorities.’’ Id. (citing
21 U.S.C. 823(f)(5)).
Finally, the Show Cause Order
notified Respondent of his right to
request a hearing on the allegations or
to submit a written statement in lieu of
a hearing, the procedure for electing
either option, and the consequence of
failing to elect either option. Id. at 2–3
(citing 21 CFR 1301.43). The
Government also included with the
Order a sample Request for Hearing
form. Id. at 4.
E:\FR\FM\18AUN1.SGM
18AUN1
50036
Federal Register / Vol. 80, No. 159 / Tuesday, August 18, 2015 / Notices
The Government represents that on
July 21, 2014, the Show Cause Order
was served on Respondent by certified
mail, and there is no dispute that
service occurred, as on August 8, 2014,
the Hearing Clerk, Office of
Administrative Law Judges, received a
letter from Respondent. Request for
Final Agency Action, at 3; see also GX
10. In the letter, Respondent responded
to each of the Government’s allegations.
GX 10, at 1–2. Respondent did not,
however, request a hearing.
Based on Respondent’s letter, I find
that he had waived his right to a hearing
on the allegations. 21 CFR 1301.43(c).
However, pursuant to 21 CFR
1301.43(c), I deem Respondent’s letter
to be his ‘‘written statement [of] position
on the matters of fact and law involved’’
in the proceeding.
Thereafter, on December 12, 2014, the
Government submitted its Request for
Final Agency Action along with the
Investigative Record. Having reviewed
the Government’s evidence as well as
Respondent’s Statement of Position, I
make the following findings of fact.
Findings
asabaliauskas on DSK5VPTVN1PROD with NOTICES
Respondent’s Registration and Licensing
Status
Respondent previously held DEA
Certificate of Registration BB6473538,
pursuant to which he was authorized to
dispense controlled substances in
schedules II–V as a practitioner, at Care
Plus Medical Group (CPMG) in Creve
Coeur, Missouri. GX 3. According to a
DEA Diversion Investigator (DI),
following an investigation into CPMG
by DEA, Respondent voluntarily
surrendered his registration on
November 9, 2011, and on the form
manifesting the surrender, Respondent
acknowledged that he was surrendering
his registration ‘‘[i]n view of my alleged
failure to comply with the Federal
requirements pertaining to controlled
substances.’’ GX 5, at 1; GX 11, at 3. The
next day, Respondent’s registration was
retired by the Agency. GX 2, at 2.
On January 12, 2012, Respondent
applied for a new registration. GX 12, at
2. However, on March 5, 2012,
following an interview with DEA
Investigators regarding his activities at
CPMG, Respondent withdrew this
application. Id. at 2–3.
On March 14, 2013, Respondent
submitted a new application, seeking
authority to dispense controlled
substances in schedules II through V, at
the registered location of Hometown
Urgent Care, 4387 Winston Ave,
Covington, KY. GX 7, at 1. It is this
application which is at issue in this
proceeding.
VerDate Sep<11>2014
17:02 Aug 17, 2015
Jkt 235001
On the application, Respondent was
required to answer four questions,
including number two, which asked:
‘‘Has the Respondent ever surrendered
(for cause) or had a federal controlled
substance registration revoked,
suspended, restricted or denied, or is
any such action pending?’’ Id. at 2.
Respondent answered ‘‘N’’ for no. Id.
Respondent also holds valid medical
licenses in Ohio and Kentucky. These
licenses expire on July 1, 2017 and
February 29, 2016, respectively.1
The Investigation of Respondent
According to a DI, Respondent was
previously employed at CPMG from July
11, 2011 through November 4, 2011. GX
11, at 3 (Declaration of Diversion
Investigator). CPMG was owned by Scott
Whitney, and Respondent was the
clinic’s sole physician. Id. at 2.
In August 2011, another DI received
an anonymous tip alleging that CPMG
was diverting controlled substances. Id.
The tipster alleged that individuals
could walk into the clinic without an
appointment, could consult with a
doctor in exchange for $250 in cash, that
CPMG did not accept insurance, and
that CPMG ‘‘had an in-house
pharmacy.’’ Id. Subsequently, the DI
determined that Mr. Whitney ‘‘had prior
ownership interests in other pain clinics
in the State of Florida’’ that had
‘‘dispensed oxycodone’’ but had ‘‘since
closed.’’ Id.
On November 9, 2011, the DI
interviewed Respondent. Id. at 3.
Respondent told the DI that at some
point prior to starting at CPMG,
Whitney had requested that Respondent
pre-sign DEA–222 Forms, which are
required to order schedule II drugs such
as oxycodone, see 21 U.S.C. 828(a), ‘‘as
a way to start the business.’’ Id. Whitney
mailed approximately twenty DEA–222
forms to Respondent, who signed them
and mailed them back to Whitney. Id.
According to the DI, Whitney used at
least one of the pre-signed order forms
to place orders for 2,000 du of
oxycodone 30 mg and 1,000 oxycodone
10/325 mg from State Pharmaceuticals,
Inc. on June 29, 2011. Id., see also GX
4. The DI also found that Respondent
‘‘authorized [] Whitney to place an order
for controlled substances under his DEA
. . . registration without executing a
power of attorney for him,’’ a violation
of 21 CFR 1305.05(a). Id.
After the conclusion of the interview,
the DI asked Respondent if he would
voluntarily surrender his DEA
1 The Government provided copies of online
license searches which show that Respondent is
licensed as an osteopathic physician in Ohio and
Kentucky.
PO 00000
Frm 00052
Fmt 4703
Sfmt 4703
registration. Id. at 3. Respondent agreed
to do so, and executed a Voluntary
Surrender Form. Id.; see also GX 5.
On January 11, 2013, Respondent
submitted an application for renewal of
his Ohio medical license. GX 6, at 1.
The application included a question
which asked: ‘‘Have you surrendered,
consented to limitation of, or to
suspension, reprimand or probation
concerning, a license to practice any
healthcare profession or state or federal
privileges to prescribe controlled
substances in any jurisdiction other
than Ohio?’’ Id. at 3. Respondent
answered ‘‘NO.’’ Id.
As noted above, on March 14, 2013,
Respondent applied for a new
registration. Thereafter, on May 22,
2013, a DI queried the Ohio Automated
Rx Reporting System (OARRS), using
Respondent’s previously surrendered
DEA registration (BB6473538). GX 12, at
3. The OARRS report showed that
Respondent had issued two controlled
substance prescriptions after he
surrendered his registration: 1) on May
5, 2012, for 60 tablets of Lyrica 75 mg
(a schedule V controlled substance) on
May 5, 2012; and 2) on September 12,
2012, for Zutripro 120 ml (a schedule III
cough syrup containing hydrocodone).
Id. at 3–4.
The DI then obtained copies of both
prescriptions. Id. at 4. The first
prescription, which is dated May 5,
2012, was for 60 capsules of Lyrica 75
mg, and was printed on a prescription
form for Urgent Care of Fairfield,
including its street address. GX 8. The
prescription includes a handwritten
signature of ‘‘Art Bell DO’’ above ‘‘Art
Bell DO,’’ which is printed below the
signature line. Id. However, no DEA
number appears on the prescription. Id.
The second prescription, which is
dated September 12, 2012, was for
‘‘Bromfed DM 2mg-30mg-10mg/5ml
Syrup,’’ a non-controlled drug, and was
also on a printed form bearing the name
of Urgent Care of Fairfield and its
address. GX 9. However, the drug name
is lined-out and the word ‘‘Zutripro’’ is
handwritten above it. Id. Zutipro is a
schedule III controlled substance which
contains hydrocodone. As with the
previous prescription, the signature line
contains a handwritten signature of ‘‘Art
Bell DO,’’ with ‘‘Art Bell DO’’ printed
below the signature line. Id. Also
written on the prescription is the
notation: ‘‘per Katie Allen.’’ Again, no
DEA number appears on the
prescription.2 Id. According to the DI, on
the dates that each prescription was
issued, Respondent was working at
2 GX 8 and GX 9 also include copies of the
dispensing labels for each prescription.
E:\FR\FM\18AUN1.SGM
18AUN1
Federal Register / Vol. 80, No. 159 / Tuesday, August 18, 2015 / Notices
Urgent Care of Fairfield in Hamilton,
Ohio. GX 12, at 4.
Respondent’s Statement of Position
asabaliauskas on DSK5VPTVN1PROD with NOTICES
In his response to the Order to Show
Cause, Respondent stated that he reapplied for a DEA registration on March
14, 2013, ‘‘not as a physician seeking
authorization to handle controlled
substances in Schedules II through V at
a proposed registered address of 4387
Winston Avenue, Covington, Kentucky
[] but to satisfy insurance company
requirements.’’ GX 10, at 1 (emphasis in
original). He asserted that ‘‘many
medical facilities require that their
physicians have a DEA registration, and
that ‘‘I hardly ever wrote for any
controlled substances prior to my
employment with Care Plus Medical
Group.’’ Id.
Regarding the allegation that he
materially falsified his DEA application
when he provided a ‘‘no’’ answer to
question two, Respondent asserted that
he provided the answer because ‘‘I
voluntarily surrendered my
registration.’’ Id. (emphasis in original.)
He then maintained that ‘‘the DEA agent
advised me to do so stating that it most
likely would be returned to me within
2–4 weeks. Since I voluntarily
surrendered the registration and no one
mentioned (for cause), I answered the
question ‘‘no.’’ Id. (emphasis in
original). Respondent added that he
‘‘misunderstood and was completely
unaware that by voluntarily
surrendering one’s DEA registration
equals voluntarily surrendering (for
cause).’’ Id. (emphasis in original). He
further stated that ‘‘semantics may have
played a part in the confusion of this
situation. Please know that the thought
never crossed my mind to commit a
fraudulent act. I apologize for the
confusion.’’ Id.3
As for the two prescriptions,
Respondent denied having issued them.
More specifically, he stated: ‘‘As for the
two prescriptions that I allegedly wrote
for Lyrica 75 mg and Zutripro 120ml. I
know nothing about this.’’ Id. He then
questioned whether there ‘‘was a
possibility that a substitute was given by
the nurse without my approval because
3 As for the false answer he provided on the
application for his Ohio license, Applicant stated
that ‘‘the renewal of my application for an Ohio
license was an oversight’’ and that he had reapplied for renewal of his Kentucky and Missouri
licenses and stated on both ‘‘that I had voluntarily
surrendered my DEA registration.’’ GX 10, at 2. He
wrote that ‘‘I mistakenly thought I had checked the
box that said I had voluntarily surrendered my DEA
registration. . . . Therefore, I checked the box
asking ‘if anything had changed since my last
renewal?’ ‘no’. [sic] I did not intend to deceive
anyone. It was an honest mistake for which I
apologize.’’ Id.
VerDate Sep<11>2014
17:02 Aug 17, 2015
Jkt 235001
insurance would not cover the nonnarcotic prescription that I had
originally written?’’ Id. He then added
that ‘‘I suppose anything is possible in
this circumstance, but rest assured, that
I have not written any prescriptions for
controlled substances since the
surrendering of my DEA registration on
November 9, 2011.’’ Id.
Respondent did admit that he presigned 20 DEA–222 forms and that he
sent the forms to Whitney and failed to
execute a power of attorney authorizing
Whitney to order the drugs. However,
he then contended that the allegation 4
that he ‘‘arranged with Mr. Whitney to
order Schedule II controlled substances
under [his] previous DEA registration’’
was not a correct statement, because
‘‘Mr. Whitney arranged this with me—
I did not know how to order controlled
substances.’’ Id. Continuing,
Respondent wrote: ‘‘[a]gain, that action
´
was pure naivete and ignorance of the
law on my part’’ and ‘‘saying I’m sorry
does not even begin to express my
remorse . . . [n]or does it alleviate the
feelings of stupidity for my actions
because of the poor judgment that I used
on that day.’’ Id.
Respondent concluded his letter by
stating that he ‘‘did not knowingly tell
lies, nor . . . intentionally try to deceive
anyone.’’ Id. He expressed the hope that
his letter ‘‘conveys [his] remorse’’ and
stated that he ‘‘would also like to be
able to retire in a few years with my
good name intact and above reproach.’’
Id.
Discussion
Section 303(f) of the Controlled
Substances Act provides that an
application for a practitioner’s
registration may be denied upon a
determination ‘‘that the issuance of such
registration would be inconsistent with
the public interest.’’ 21 U.S.C. 823(f). In
making the public interest
determination, the CSA requires the
consideration of the following factors:
(1) The recommendation of the
appropriate State licensing board or
professional disciplinary authority.
(2) The Applicant’s experience in
dispensing . . . controlled substances.
(3) The Applicant’s conviction record
under Federal or State laws relating to
the manufacture, distribution, or
dispensing of controlled substances.
(4) Compliance with applicable State,
Federal, or local laws relating to
controlled substances.
(5) Such other conduct which may
threaten the public health and safety.
Id.
4 This statement appears as an allegation in the
Order to Show Cause. See GX 1, at 2.
PO 00000
Frm 00053
Fmt 4703
Sfmt 4703
50037
‘‘These factors are . . . considered in
the disjunctive.’’ Robert A. Leslie, M.D.,
68 FR 15227, 15230 (2003). I ‘‘may rely
on any one or a combination of factors,
and may give each factor the weight [I]
deem[] appropriate in determining
whether . . . an application for
registration [should be] denied.’’ Id.
Moreover, while I am required to
consider each of the factors, I ‘‘need not
make explicit findings as to each one.’’
MacKay v. DEA, 664 F.3d 808, 816 (10th
Cir. 2011) (quoting Volkman, 567 F.3d
215, 222 (6th Cir. 2009) (quoting Hoxie,
419 F.3d 477, 482 (6th Cir. 2005))).
‘‘In short, this is not a contest in
which score is kept; the Agency is not
required to mechanically count up the
factors and determine how many favor
the Government and how many favor
the registrant. Rather, it is an inquiry
which focuses on protecting the public
interest; what matters is the seriousness
of the registrant’s misconduct.’’ Jayam
Krishna-Iyer, 74 FR 459, 462 (2009).
Also, pursuant to section 304(a)(1),
the Attorney General is authorized to
suspend or revoke a registration ‘‘upon
a finding that the registrant . . . has
materially falsified any application filed
pursuant to or required by this
subchapter.’’ 21 U.S.C. 824(a)(1). It is
well established that the various
grounds for revocation or suspension of
an existing registration that Congress
enumerated in section 304(a), 21 U.S.C.
824(a), are also properly considered in
deciding whether to grant or deny an
application under section 303. See The
Lawsons, Inc., 72 FR 74334, 74337
(2007); Anthony D. Funches, 64 FR
14267, 14268 (1999); Alan R.
Schankman, 63 FR 45260 (1998); Kuen
H. Chen, 58 FR 65401, 65402 (1993).
Thus, the allegation that Respondent
materially falsified his application is
properly considered in this proceeding.
See Samuel S. Jackson, 72 FR 23848,
23852 (2007). Moreover, just as
materially falsifying an application
provides a basis for revoking an existing
registration without proof of any other
misconduct, see 21 U.S.C. 824(a)(1), it
also provides an independent and
adequate ground for denying an
application. The Lawsons, 72 FR at
74338; cf. Bobby Watts, M.D., 58 FR
46995 (1993).
The Government has ‘‘[t]he burden of
proving that the requirements for . . .
registration . . . are not satisfied.’’ 21
CFR 1301.44(d). Having considered all
of the public interest factors, as well as
the separate allegation that Respondent
materially falsified his application for a
DEA registration, I conclude that the
Government has established a prima
facie case to deny his application. While
I have considered Respondent’s
E:\FR\FM\18AUN1.SGM
18AUN1
50038
Federal Register / Vol. 80, No. 159 / Tuesday, August 18, 2015 / Notices
asabaliauskas on DSK5VPTVN1PROD with NOTICES
Statement of Position, I do not find his
expressions of remorse persuasive and
hold that he has not produced sufficient
evidence to refute the Government’s
prima facie case. Accordingly, I will
order that his application be denied.
Material Falsification
As found above, on March 4, 2013,
Respondent applied for a new
registration and answered ‘‘N’’ or no to
the question: ‘‘[h]as the applicant ever
surrendered (for cause) or had a federal
controlled substance registration
revoked, suspended, restricted or
denied, or is any such action pending?’’
Respondent’s answer was false because
on November 9, 2011, he voluntarily
surrendered his DEA registration
following an interview with a DEA
Investigator regarding his activities at
CPMG, during which he admitted to
signing schedule II order forms while
failing to execute a power of attorney as
required under DEA’s regulation. He
then provided those forms to CPMG’s
owner, thereby by allowing the latter to
order 2,000 du of oxycodone 30 and
1,000 du of oxycodone 10/325.
This was a violation of DEA
regulations and federal law. See 21
U.S.C. 842(a)(5) (‘‘It shall be unlawful
for any person . . . to refuse or
negligently fail to make, keep, or furnish
any record, report, notification,
declaration, order or order form,
statement, invoice, or information
required under this subchapter.’’); 21
CFR 1305.04(a) (‘‘Only persons who are
registered with DEA under section 303
of the Act . . . to handle Schedule I or
II controlled substances . . . may obtain
and use DEA From 222 . . . for these
substances.’’); id. § 1305.05(a) (‘‘A
registrant may authorize one or more
individuals . . . to issue orders for
Schedule I and II controlled substances
on the registrant’s behalf by executing a
power of attorney for each such
individual. . . .’’).
Respondent nonetheless asserts that
he misunderstood the question. He
claims that because he ‘‘voluntarily
surrendered’’ his registration’’ and ‘‘no
one mentioned (for cause),’’ he did not
believe that he had surrendered his
registration ‘‘for cause.’’ However, the
circumstances surrounding the
interview during which he surrendered
his registration, coupled with the
language of the voluntary surrender
form on which Respondent
acknowledged that he was surrendering
his registration ‘‘[i]n view of my alleged
failure to comply with the Federal
requirements pertaining to controlled
substances’’ GX 5, at 1, are sufficient to
support the conclusion that Respondent
surrendered his registration ‘‘for cause.’’
VerDate Sep<11>2014
17:02 Aug 17, 2015
Jkt 235001
I also conclude that Respondent’s
answer was materially false. As the
Supreme Court has explained, ‘‘[t]he
most common formulation’’ of the
concept of materiality ‘‘is that a
concealment or misrepresentation is
material if it ‘has a natural tendency to
influence, or was capable of influencing,
the decision of’ the decisionmaking
body to which it was addressed.’’
Kungys v. United States, 485 U.S. 759,
770 (1988) (quoting Weinstock v. United
States, 231 F.2d 699, 701 (D.C. Cir.
1956)) (other citation omitted); see also
United States v. Wells, 519 U.S. 482,
489 (1997) (quoting Kungys, 485 U.S. at
770).
‘‘[I]t has never been the test of
materiality that the misrepresentation or
concealment would more likely than not
have produced an erroneous decision,
or even that it would more likely than
not have triggered an investigation, but
rather, whether the misrepresentation or
concealment was predictably capable of
affecting, i.e., had a natural tendency to
affect, the official decision.’’ Kungys,
485 U.S. at 771. While the evidence
must be ‘‘clear, unequivocal, and
convincing,’’ the ‘‘ultimate finding of
materiality turns on an interpretation of
the substantive law.’’ Id. at 772 (int.
quotations and citations omitted).
Notwithstanding that the Agency did
not grant his application, Respondent’s
false answer to question two was clearly
‘‘capable of affecting’’ the decision of
whether to grant his application because
he surrendered his registration in
response to allegations that he violated
DEA regulations, and under the public
interest standard, the Agency is required
to consider the Applicant’s
‘‘[c]ompliance with applicable State,
Federal, or local laws relating to
controlled substances.’’ 21 U.S.C.
823(f)(4). Accordingly, I conclude that
Respondent materially falsified his
March 2013 application for registration.
In his statement, Respondent
contends that ‘‘semantics may have
played a part in the confusion of this
situation. Please know that the thought
never crossed my mind to commit a
fraudulent act. I apologize for the
confusion.’’ GX 10, at 1.
Respondent’s explanation is not
persuasive. Here, the evidence also
shows that when Respondent applied
for his Ohio medical license, the State’s
application contained the following
question: ‘‘Have you surrendered,
consented to limitation of, or to
suspension, reprimand or probation
concerning . . . state or federal
privileges to prescribe controlled
substances in any jurisdiction other
than Ohio?’’ GX 6, at 3. Respondent,
however, answered ‘‘NO.’’ Id. Notably,
PO 00000
Frm 00054
Fmt 4703
Sfmt 4703
in contrast to the question on the DEA
application, the Ohio question did not
ask whether he surrendered ‘‘for cause’’
and thus presented no issue of—in
Respondent’s view—semantics. Further,
Respondent does not claim that he was
confused by the question.5 Id. Yet
Respondent still provided a false answer
to the Ohio question. Thus, I reject his
claim of confusion and conclude that
his false answer on the Ohio application
is probative of his intent in answering
the DEA question and that his intent
was fraudulent. Cf. Fed. R. Evid. R.
404(b)(2).
This conclusion finds further support
in the circumstances surrounding the
March 5, 2012 interview, which resulted
in his withdrawal of the January 5, 2012
application. While the Government did
not submit any evidence as to whether
Respondent truthfully answered
Question Two on this application, a
DEA Investigator provided a sworn
statement that on March 5, 2012, he
interviewed Respondent regarding his
activities at CPMG.6 See GX 12, at 2.
According to the DI, ‘‘[a]t the conclusion
of the interview, DEA investigators
informed [Respondent’s] legal counsel
that [he] could face criminal charges
based on his previous handling of
controlled substances on behalf of
CPMG.’’ Id. at 2–3. Thereafter,
5 Rather, Respondent asserts that his answer on
the Ohio medical license application ‘‘was an
oversight,’’ that he ‘‘mistakenly thought I had
checked the box that said I had voluntarily
surrendered my DEA registration,’’ and that ‘‘I
checked the box asking ‘if anything had changed
since my last renewal?’ ‘no.’ ’’ GX 10, at 2. However,
Respondent filed his Ohio medical license
application on January 11, 2013, and according to
the Web site of the State Medical Board, ‘‘Doctors
of Osteopathic Medicine [DOs] are required to
renew their licenses biennially in order to maintain
an active certificate to practice.’’ See https://
www.med.ohio.gov/RenewalCME/
DoctorofOstepathicMedicine(DO).aspx.
As found above, Respondent surrendered his
DEA registration on November 9, 2011, and given
that his Ohio license was good for two years, I
conclude that his previous Ohio application was
filed before he surrendered his DEA registration.
Thus, at the time he filed his Ohio medical license
application, something ‘‘had changed since [his]
last renewal.’’ GX 10, at 2. Moreover, the Ohio
application clearly instructed: ‘‘Please review all
information you have provided. Click on the
‘Review’ button to change any information given.
. . .’’ GX 6, at 2. The form also included the
following statements: ‘‘I understand that submitting
a false, fraudulent, or forged statement or document
or omitting a material fact in obtaining licensure
may be grounds for disciplinary action against my
license’’ and ‘‘Under penalty of law, I hereby swear
or affirm that the information I have provided in the
application is complete and correct, and that I have
complied with all criteria for applying on line.’’ Id.
at 6.
6 Agency records, of which I take official notice,
see 21 CFR 1316.59(e), show that Applicant also
answered ‘‘No’’ to Liability Question Two on his
January 2012 application. There is, however, no
evidence that his response was specifically
addressed by the investigating DI at the time.
E:\FR\FM\18AUN1.SGM
18AUN1
Federal Register / Vol. 80, No. 159 / Tuesday, August 18, 2015 / Notices
Respondent consulted with his attorney
and decided to withdraw his
application. Id. at 3. Given that the
March 5, 2012 interview involved the
same matters as had been discussed at
the time Respondent surrendered his
registration and that he had been
threatened with criminal prosecution,
Respondent cannot credibly argue that,
at the time he submitted the March 2013
application, he remained confused as to
whether he had previously surrendered
the registration ‘‘for cause.’’
I therefore conclude that substantial
evidence supports findings that
Respondent materially falsified his
application for March 2013 application
for registration when he failed to
disclose that he had surrendered his
DEA registration ‘‘for cause,’’ and that
he did so intentionally. See GX 10, GX
12 at 2–3. I further conclude that these
findings support the denial of
Respondent’s application.
The Public Interest Analysis
asabaliauskas on DSK5VPTVN1PROD with NOTICES
The Government also argues that
Respondent’s application should be
denied on the separate ground that his
registration is ‘‘inconsistent with the
public interest.’’ 21 U.S.C. 823(f). More
specifically, the Government argues that
factors two (experience in dispensing),
four (compliance with applicable laws
related to controlled substances) and
five (other conduct which may threaten
public health and safety), support the
denial of his application.7 Government’s
Request for Final Agency Action, at 10.
7 I acknowledge that Applicant remains licensed
in Kentucky, the State in which he seeks
registration, and therefore, he meets the CSA’s
prerequisite for holding a practitioner’s registration
in that State. See 21 U.S.C. 823(f) (‘‘The Attorney
General shall register practitioners . . . to dispense
. . . controlled substances . . . if the applicant is
authorized to dispense . . . controlled substances
under the laws of the State in which he practices.’’);
see also id. § 802(21) (‘‘The term ‘practitioner’
means a physician . . . or other persons licensed,
registered, or otherwise permitted, by the United
States or the jurisdiction in which he practices . . .
to distribute, dispense, . . . [or] administer . . . a
controlled substance.’’).
However, the possession of state authority ‘‘is not
dispositive of the public interest inquiry.’’ George
Mathew, 75 FR 66138, 66145 (2010), pet. for rev.
denied, Mathew v. DEA, 472 Fed. Appx. 453 (9th
Cir. 2012); see also Patrick W. Stodola, 74 FR
20727, 20730 n.16 (2009). As the Agency has long
held, ‘‘the Controlled Substances Act requires that
the Administrator . . . make an independent
determination [from that made by state officials] as
to whether the granting of controlled substance
privileges would be in the public interest.’’
Mortimer Levin, 57 FR 8680, 8681 (1992).
Accordingly, this factor is not dispositive either for,
or against, the granting of Respondent’s application.
Paul Weir Battershell, 76 FR 44359, 44366 (2011)
(citing Edmund Chein, 72 FR 6580, 6590 (2007),
pet. for rev. denied, Chein v. DEA, 533 F.3d 828
(D.C. Cir. 2008)).
As for factor three, there is no evidence that
Applicant has been convicted of an offense
VerDate Sep<11>2014
17:02 Aug 17, 2015
Jkt 235001
With regard to factors two and four,
the Government alleges that Respondent
issued two controlled-substance
prescriptions after he surrendered his
registration. In his written statement,
Respondent denies any knowledge of
both prescriptions, and posits ‘‘that a
substitute was given by a nurse without
[his] approval because insurance would
not cover the non-narcotic prescription
that [he] had originally written?’’ GX 10,
at 2.
Having reviewed the signatures on the
prescriptions with the other documents
in the record which indisputably
contain Respondent’s signature (i.e., his
written statement of position, the
voluntary surrender form, and the DEA
Form 222), I conclude that Respondent
signed both prescriptions. See United
States v. Clifford, 704 F.2d 86, 90 n.5
(3d Cir. 1983) (‘‘[A] jury can compare a
known handwriting sample with
another sample to determine if the
handwriting in the latter sample is
genuine. The jury can make that
comparison without the benefit of
expert witnesses.’’) (citations omitted);
see also 28 U.S.C. 1731 (‘‘The admitted
or proved handwriting of any person
shall be admissible, for purposes of
comparison, to determine genuineness
of other handwriting attributed to such
person.’’).
Notwithstanding that Respondent did
not include a DEA number on the
prescription, I find that Respondent
unlawfully issued the May 5, 2012
prescription for Lyrica. See 21 U.S.C.
841(a)(1) (‘‘Except as authorized by this
subchapter, it shall be unlawful for any
person knowingly or intentionally . . .
to . . . dispense . . . a controlled
substance.’’); id. § 822(a)(2) (Every
person who dispenses . . . shall obtain
from the Attorney General a registration
issued in accordance with the rules and
regulations promulgated by him.’’); 21
CFR 1306.03(a)(2) (‘‘A prescription for a
controlled substance may be issued only
by an individual practitioner who is
. . . [e]ither registered or exempted
from registration. . . .’’); Cf. id.
§ 843(a)(2) (‘‘It shall be unlawful for any
person knowing or intentionally . . . to
use in the course of the . . . dispensing
of a controlled substance . . . a
registration number which is fictitious,
‘‘relating to the manufacture, distribution or
dispensing of controlled substances.’’ 21 U.S.C.
823(f)(3). However, there are a number of reasons
why even a person who has engaged in misconduct
may never have been convicted of an offense under
this factor, let alone prosecuted for one. Dewey C.
MacKay, 75 FR 49956, 49973 (2010), pet. for rev.
denied MacKay v. DEA, 664 F.3d 808 (10th Cir.
2011). The Agency has therefore held that ‘‘the
absence of such a conviction is of considerably less
consequence in the public interest inquiry’’ and is
therefore not dispositive. Id.
PO 00000
Frm 00055
Fmt 4703
Sfmt 4703
50039
revoked, suspended, [or] expired.
. . .’’).
However, I do not find the evidence
sufficient to sustain the allegation as to
the September 12, 2012 prescription. As
the evidence shows, the prescription
was originally issued for Bromfed DM (a
non-narcotic), but was then changed to
Zutripro, a schedule III controlled
substance, and bears the handwritten
notation ‘‘per Katie Allen.’’ The
Government offered no further evidence
regarding the circumstances
surrounding the change in the
prescription. It did not explain who Ms.
Katie Allen is and where she was
working on September 12, 2012. Nor did
it offer any evidence that it interviewed
the pharmacist who filled the
prescription, the patient, or Ms. Allen.
As found above, Respondent also
admitted that he pre-signed twenty
schedule II order forms and that he
mailed them to Whitney, so that
Whitney could order controlled
substances for his pain clinic and ‘‘start
the business,’’ which Whitney then used
to order oxycodone. Respondent
violated federal law and Agency
regulations because while he clearly
authorized Whitney to order the drugs,
he failed to execute a power of attorney
for him. See 21 U.S.C. 842(a)(5); 21 CFR
1305.04(a); id. § 1305.05(a).8
Respondent admitted to these
violations. GX 10, at 2. However, he
then stated that he ‘‘did not know how
to order controlled substances’’ and that
´
‘‘that action was pure naivete and
ignorance of the law on my part.’’ 9 GX
10, at 2. This is not a particularly
persuasive explanation for one who
seeks a DEA registration.
I therefore conclude that the evidence
with respect to factors two and four
supports the conclusion that issuing
Respondent a new registration ‘‘would
be inconsistent with the public
interest.’’ 21 U.S.C. 823(f).
8 Of further note, Whitney could not have
obtained the order forms without Respondent
having provided him with his DEA Registration
number, which is pre-printed on the forms when
issued by DEA. See GX 4; see also 21 CFR
1305.04(a). However, the Agency has repeatedly
held that a registrant is strictly liable for any
misconduct engaged in by a person to whom a
registrant entrusts his registration. See Satinder
Dang, 76 FR 51424, 51429 (2011); Rosemary Jacinta
Lewis, 72 FR 4035, 4041 (2007). The evidence
offered by the Government as to whether Whitney
and Respondent were diverting controlled
substances at CPMG does not, however, create more
than a suspicion.
9 It is well settled that ‘‘ignorance of the law or
a mistake of law is no defense.’’ Cheek v. United
States, 498 U.S. 192, 199 (1991). Moreover, the
principle ‘‘applies whether the law be a statute or
a duly promulgated and published regulation.’’
United States v. International Minerals & Chemical
Corp., 402 U.S. 558, 563 (1971).
E:\FR\FM\18AUN1.SGM
18AUN1
asabaliauskas on DSK5VPTVN1PROD with NOTICES
50040
Federal Register / Vol. 80, No. 159 / Tuesday, August 18, 2015 / Notices
Factor Five
The Government further argues that
Respondent committed actionable
misconduct under factor five when he
failed to disclose the surrender of his
DEA registration on his application to
the Ohio Medical Board. Request for
Final Agency Action, at 11. In support
of its contention, the Government cites
David A. Hoxie, M.D., 69 FR 51477,
51478 (2004), for the proposition that
providing false answers on a state
professional license application
‘‘demonstrate[s] questionable candor.’’
Id. (citing Bernard C. Musselman, M.D.,
64 FR 55965 (1999)). It also cites
Leonard E. Reeves, III, 63 FR 44471,
44784 (1998), which ordered a stayed
revocation of the physician’s DEA
registration relying, in part, on a state
board’s denial of the physician’s
application for a medical license based
on the physician’s ‘‘total lack of
truthful, accurate and complete answers
on his written application for
licensure.’’ 10
Undoubtedly, providing a materially
false answer to a question on a state
medical license application is probative
evidence of whether a registrant or
applicant demonstrates ‘‘questionable
candor.’’ However, here, in contrast to
Reeves, there has been no adjudication
by the State of Ohio and Respondent
retains a valid osteopathic license in
that State. Thus, the question remains as
to whether this Agency should be
adjudicating this allegation in the first
instance, especially where, as here,
Respondent is neither registered in Ohio
nor seeks registration in that State.
To be sure, Hoxie went beyond Reeves
by holding that the physician’s
falsifications of his medical license
applications were actionable under
factor five even in the absence of a state
board finding. Hoxie, however,
preceded the Supreme Court’s decision
in Gonzales v. Oregon, 546 U.S. 243
(2006). Therein, the Supreme Court
explained that the CSA ‘‘manifests no
intent to regulate the practice of
medicine generally’’ and that ‘‘[t]he
structure and operation of the CSA
presume and rely upon a functioning
medical profession regulated under the
States’ police powers.’’ Id. at 270.
While the Government contends that
Respondent’s false statement on his
Ohio medical license application can be
considered as a separate act of
actionable misconduct under factor five,
it offers no explanation as to why it is
consistent with Gonzales, that DEA,
rather than the Ohio Medical Board,
10 The physician was not, however, registered in
the State which found that he had submitted a false
application for a second medical license.
VerDate Sep<11>2014
17:02 Aug 17, 2015
Jkt 235001
should be the first body to adjudicate
the issue. Nor does the Government
offer any explanation as to why the
Ohio Board is incapable of enforcing its
own laws. Finally, the Government does
not even cite the applicable provision of
Ohio law, let alone explain whether
there is a materiality requirement under
Ohio law, and if so, what the standard
is under Ohio law.
While the Government’s position
would be stronger if Respondent was
registered in Ohio—on the theory that
the falsification of his state application
resulted in the State granting him the
osteopathic license necessary to obtain
his DEA registration,11 see 21 U.S.C.
823(f)—Respondent is neither
registered, nor seeking registration, in
Ohio. Thus, in the absence of a state
board finding, I decline to follow Hoxie
and do not consider Respondent’s
falsification of his Ohio application
other than for the limited purpose of
evaluating his claim that he was
confused by the wording on his DEA
application.12
Summary of the Government’s Prima
Facie Case
As found above, Respondent
intentionally and materially falsified his
March 14, 2013 application for a DEA
registration. This finding alone provides
an adequate basis to deny his
application. 21 U.S.C. 824(a)(1) and
843(a)(4)(A).
The evidence also shows that
Respondent violated DEA regulations
when he provided schedule II order
forms to Mr. Whitney, CPMG’s owner,
and authorized him to order oxycodone
without having executed a power of
attorney as required by 21 CFR
1305.05(a). Finally, the evidence also
shows that Respondent issued a
prescription for Lyrica, a schedule V
controlled substance, when he was no
longer registered, and thus violated 21
U.S.C. 841(a)(1) and 822(a)(2). I
therefore find that the Government’s
evidence under factors two and four is
sufficient to conclude that the
Government has met its prima facie
burden on the issue of whether the
issuance of a registration ‘‘would be
11 It seems unlikely that a physician would falsify
his state medical license application but then
truthfully disclose a sanction against his federal
registration on his DEA application.
12 Notably, Hoxie does not cite Reeves, but rather
Musselman, as authority for the proposition. See 69
FR at 51479. While Musselman discusses the factual
findings of a state board proceeding which was
based, in part, on an allegation that the physician
had falsified a state license application, the state
board did not find the allegation proved, and in
discussing factor five, the Agency’s decision
discusses only the physician’s falsification of his
DEA application. See 64 FR at 55967. Thus,
Musselman clearly does not support Hoxie.
PO 00000
Frm 00056
Fmt 4703
Sfmt 4703
inconsistent with the public interest.’’
21 U.S.C. 823(f).
Sanction
Where, as here, the Government has
established grounds to deny an
application, Respondent must then
‘‘present[] sufficient mitigating
evidence’’ to show why he can be
entrusted with a new registration.
Samuel S. Jackson, 72 FR 23848, 23853
(2007) (quoting Leo R. Miller, 53 FR
21931, 21932 (1988)). ‘‘‘Moreover,
because ‘past performance is the best
predictor of future performance,’ ALRA
Labs, Inc. v. DEA, 54 F.3d 450, 452 (7th
Cir. 1995), [DEA] has repeatedly held
that where [an applicant] has committed
acts inconsistent with the public
interest, the [applicant] must accept
responsibility for [his] actions and
demonstrate that [he] will not engage in
future misconduct.’’ Jayam Krishna-Iyer,
74 FR 459, 463 (2009) (citing Medicine
Shoppe, 73 FR 364, 387 (2008)); see also
Jackson, 72 FR at 23853; John H.
Kennedy, 71 FR 35705, 35709 (2006);
Cuong Tron Tran, 63 FR 64280, 64283
(1998); Prince George Daniels, 60 FR
62884, 62887 (1995).13
While an applicant must accept
responsibility for his misconduct and
demonstrate that he will not engage in
future misconduct in order to establish
that its registration is consistent with
the public interest, DEA has repeatedly
held that these are not the only factors
that are relevant in determining the
appropriate sanction. See, e.g., Joseph
Gaudio, 74 FR 10083, 10094 (2009);
Southwood Pharmaceuticals, Inc., 72 FR
36487, 36504 (2007). Obviously, the
egregiousness and extent of a
registrant’s misconduct are significant
factors in determining the appropriate
sanction. See Jacobo Dreszer, 76 FR
19386, 19387–88 (2011) (explaining that
a respondent can ‘‘argue that even
though the Government has made out a
prima facie case, his conduct was not so
egregious as to warrant revocation’’);
Paul H. Volkman, 73 FR 30630, 30644
(2008); see also Paul Weir Battershell,
76 FR 44359, 44369 (2010) (imposing
six-month suspension, noting that the
evidence was not limited to security and
recordkeeping violations found at first
inspection and ‘‘manifested a disturbing
pattern of indifference on the part of
[r]espondent to his obligations as a
registrant’’); Gregory D. Owens, 74 FR
36751, 36757 n.22 (2009). So too, the
Agency can consider the need to deter
similar acts, both with respect to the
13 This rule also applies to other grounds that
support the denial of an application, such as where
the Government has proven that an applicant
materially falsified his application. See Jackson, 72
FR, at 23853.
E:\FR\FM\18AUN1.SGM
18AUN1
50041
Federal Register / Vol. 80, No. 159 / Tuesday, August 18, 2015 / Notices
respondent in a particular case and the
community of registrants. See Gaudio,
74 FR at 10095 (quoting Southwood, 71
FR at 36503). Cf. McCarthy v. SEC, 406
F.3d 179, 188–89 (2d Cir. 2005)
(upholding SEC’s express adoption of
‘‘deterrence, both specific and general,
as a component in analyzing the
remedial efficacy of sanctions’’).
Having reviewed Respondent’s
Statement of Position, I conclude that he
has failed to produce sufficient evidence
to show why he should be entrusted
with a new registration. His acceptance
of responsibility is equivocal at best, as
while he appears to acknowledge his
wrongdoing with respect to his having
provided the Schedule II order forms to
Mr. Whitney, his explanation for why
he materially falsified his DEA
application is clearly disingenuous. So
too, is his assertion that he ‘‘did not
knowingly tell lies, nor . . .
intentionally try to deceive anyone.’’
Because Respondent committed
intentional misconduct when he
materially falsified his application, I
find his misconduct to be egregious.14
Accordingly, his failure to accept
responsibility for this misconduct is
reason alone to conclude that he cannot
be entrusted with a new registration.15
Moreover, the Agency has a manifest
interest in deterring misconduct on the
part of others who may contemplate
materially falsifying their applications
for registration. Accordingly, I conclude
that denial of his application is
necessary to protect the public interest.
Order
Pursuant to the authority vested in me
by 21 U.S.C. 823(f), as well as 28 CFR
0.100(b), I order that the application of
Arthur H. Bell, D.O., for a DEA
Certificate of Registration as a
practitioner be, and it hereby is, denied.
This Order is effective immediately.
Dated: August 10, 2015.
Chuck Rosenberg,
Acting Administrator.
[FR Doc. 2015–20353 Filed 8–17–15; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–392]
Bulk Manufacturer of Controlled
Substances Application: Alltech
Associates, Inc.
ACTION:
Notice of application.
Registered bulk manufacturers of
the affected basic classes, and
applicants therefore, may file written
comments on or objections to the
issuance of the proposed registration in
accordance with 21 CFR 1301.33(a) on
or before October 19, 2015.
DATES:
Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/ODXL, 8701
Morrissette Drive, Springfield, Virginia
22152. Request for hearings should be
sent to: Drug Enforcement
Administration, Attention: Hearing
Clerk/LJ, 8701 Morrissette Drive,
Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION: The
Attorney General has delegated his
authority under the Controlled
Substances Act to the Administrator of
the Drug Enforcement Administration
(DEA), 28 CFR 0.100(b). Authority to
exercise all necessary functions with
respect to the promulgation and
implementation of 21 CFR part 1301,
incident to the registration of
manufacturers, distributors, dispensers,
importers, and exporters of controlled
substances (other than final orders in
connection with suspension, denial, or
revocation of registration) has been
redelegated to the Deputy Assistant
Administrator of the DEA Office of
Diversion Control (‘‘Deputy Assistant
Administrator’’) pursuant to section 7 of
28 CFR part 0, appendix to subpart R.
In accordance with 21 CFR
1301.33(a), this is notice that on April
24, 2015, Alltech Associates, Inc., 2051
Waukegan Road, Deerfield, Illinois
60015 applied to be registered as a bulk
manufacturer of the following basic
classes of controlled substances:
ADDRESSES:
asabaliauskas on DSK5VPTVN1PROD with NOTICES
Controlled substance
Schedule
Methcathinone (1237) ..................................................................................................................................................................................
N-Ethylamphetamine (1475) ........................................................................................................................................................................
N,N-Dimethylamphetamine (1480) ..............................................................................................................................................................
4-Methylaminorex (cis isomer) (1590) .........................................................................................................................................................
Gamma Hydroxybutyric Acid (2010) ...........................................................................................................................................................
Alpha-ethyltryptamine (7249) ......................................................................................................................................................................
Lysergic acid diethylamide (7315) ...............................................................................................................................................................
2,5-Dimethoxy-4-(n)-propylthiophenethylamine (2C–T–7) (7348) ...............................................................................................................
Tetrahydrocannabinols (7370) .....................................................................................................................................................................
Mescaline (7381) .........................................................................................................................................................................................
4-Bromo-2,5-dimethoxyamphetamine (7391) ..............................................................................................................................................
4-Bromo-2,5-dimethoxyphenethylamine (7392) ..........................................................................................................................................
4-Methyl-2,5-dimethoxyamphetamine (7395) ..............................................................................................................................................
2,5-Dimethoxyamphetamine (7396) ............................................................................................................................................................
2,5-Dimethoxy-4-ethylamphetamine (7399) ................................................................................................................................................
3,4-Methylenedioxyamphetamine (7400) ....................................................................................................................................................
N-Hydroxy-3,4-methylenedioxyamphetamine (7402) ..................................................................................................................................
3,4-Methylenedioxy-N-ethylamphetamine (7404) ........................................................................................................................................
3,4-Methylenedioxymethamphetamine (7405) ............................................................................................................................................
4-Methoxyamphetamine (7411) ...................................................................................................................................................................
5-Methoxy-N-N-dimethyltryptamine (7431) .................................................................................................................................................
Alpha-methyltryptamine (7432) ...................................................................................................................................................................
Bufotenine (7433) ........................................................................................................................................................................................
Diethyltryptamine (7434) .............................................................................................................................................................................
Dimethyltryptamine (7435) ..........................................................................................................................................................................
Psilocybin (7437) .........................................................................................................................................................................................
14 Having found that Respondent’s material
falsification of his application is egregious and that
he has not accepted responsibility for the violation,
I need not decide whether the other proven
VerDate Sep<11>2014
17:02 Aug 17, 2015
Jkt 235001
violations are sufficiently egregious to support the
denial of the application.
15 As to the violation in authorizing Whitney to
order schedule II drugs, Respondent stated that this
´
was the result of ‘‘pure naivete and ignorance of the
PO 00000
Frm 00057
Fmt 4703
Sfmt 4703
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
law on my part.’’ However, Respondent has offered
no evidence of remedial actions he has taken to
demonstrate that he is now familiar with the laws
and regulations applicable to the lawful dispensing
of controlled substances.
E:\FR\FM\18AUN1.SGM
18AUN1
Agencies
[Federal Register Volume 80, Number 159 (Tuesday, August 18, 2015)]
[Notices]
[Pages 50035-50041]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2015-20353]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Arthur H. Bell, D.O.; Decision and Order
On July 15, 2014, the Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement Administration, issued an Order to
Show Cause to Arthur H. Bell, D.O. (Respondent), of Covington,
Kentucky. GX 1, at 1. The Show Cause Order proposed the denial of
Respondent's application for a DEA Certificate of Registration as a
practitioner on multiple grounds, including that he had materially
falsified his application for a registration, as well as that he had
committed acts which render his registration inconsistent with the
public interest. Id. at 1-2 (citing 21 U.S.C. 823(f) and 824(a)(1)).
As for the material falsification allegation, the Show Cause Order
alleged that on November 9, 2011, Respondent had voluntarily
surrendered his previous DEA Registration. Id. The Order then alleged
that on March 14, 2013, Respondent applied for a new DEA registration,
but materially falsified the application when he ``answered `no' to
question which asked, `[h]as the Respondent ever surrendered (for
cause) or had a federal controlled substance registration revoked,
suspended, restricted or denied, or is any such action pending?''' Id.
As for the allegations that Respondent had committed acts which
render his registration inconsistent with the public interest, the Show
Cause Order alleged that Respondent violated federal law by issuing
controlled substance prescriptions when he ``no longer possessed a DEA
registration.'' Id. at 2 (citing 21 CFR 1306.03(a)). More specifically,
the Order alleged that on May 5, 2012, Respondent had issued a
prescription for 60 tablets of Lyrica 75 mg, a schedule V controlled
substance, and on September 12, 2012, Respondent had issued a
prescription for Zutripro 120 ml, a schedule III controlled substance.
Id.
The Show Cause Order also alleged that from July 11, 2011 through
November 4, 2011, Respondent ``dispensed controlled substances on
behalf of Care Plus Medical Group (CPMG), a purported pain management
clinic formerly located in Creve Coeur, Missouri, [which] was owned by
Scott Whitney.'' Id. The Order alleged that prior to beginning his
employment with CPMG, Respondent arranged with Whitney to order
schedule II controlled substances under his previous registration and
that ``[t]o that end, . . . Whitney sent 20 DEA 222 forms to
[Respondent's] residence, and asked that [he] pre-sign them so that
controlled substances could be ordered on behalf of CPMG.'' Id. The
Order then alleged that Respondent ``pre-signed the forms, dated them .
. . and mailed them to . . . Whitney . . . [who] then used one . . . to
place orders for oxycodone 30 mg and oxycodone 10/325 mg.'' Id. The
Order alleged that this violated federal law because it ``authoriz[ed]
. . . Whitney to place an order for controlled substances under
[Respondent's] previous . . . registration without executing a power of
attorney for . . . Whitney.'' Id. (citing 21 CFR 1303.05(a)).
Next, the Show Cause Order alleged that on October 28, 2013,
Respondent falsified his application for his Ohio medical license, when
he failed to disclose that he had previously surrendered his DEA
registration. Id. at 1-2. The Order further alleged that this ``conduct
evidences a lack of candor to Ohio licensing authorities.'' Id. (citing
21 U.S.C. 823(f)(5)).
Finally, the Show Cause Order notified Respondent of his right to
request a hearing on the allegations or to submit a written statement
in lieu of a hearing, the procedure for electing either option, and the
consequence of failing to elect either option. Id. at 2-3 (citing 21
CFR 1301.43). The Government also included with the Order a sample
Request for Hearing form. Id. at 4.
[[Page 50036]]
The Government represents that on July 21, 2014, the Show Cause
Order was served on Respondent by certified mail, and there is no
dispute that service occurred, as on August 8, 2014, the Hearing Clerk,
Office of Administrative Law Judges, received a letter from Respondent.
Request for Final Agency Action, at 3; see also GX 10. In the letter,
Respondent responded to each of the Government's allegations. GX 10, at
1-2. Respondent did not, however, request a hearing.
Based on Respondent's letter, I find that he had waived his right
to a hearing on the allegations. 21 CFR 1301.43(c). However, pursuant
to 21 CFR 1301.43(c), I deem Respondent's letter to be his ``written
statement [of] position on the matters of fact and law involved'' in
the proceeding.
Thereafter, on December 12, 2014, the Government submitted its
Request for Final Agency Action along with the Investigative Record.
Having reviewed the Government's evidence as well as Respondent's
Statement of Position, I make the following findings of fact.
Findings
Respondent's Registration and Licensing Status
Respondent previously held DEA Certificate of Registration
BB6473538, pursuant to which he was authorized to dispense controlled
substances in schedules II-V as a practitioner, at Care Plus Medical
Group (CPMG) in Creve Coeur, Missouri. GX 3. According to a DEA
Diversion Investigator (DI), following an investigation into CPMG by
DEA, Respondent voluntarily surrendered his registration on November 9,
2011, and on the form manifesting the surrender, Respondent
acknowledged that he was surrendering his registration ``[i]n view of
my alleged failure to comply with the Federal requirements pertaining
to controlled substances.'' GX 5, at 1; GX 11, at 3. The next day,
Respondent's registration was retired by the Agency. GX 2, at 2.
On January 12, 2012, Respondent applied for a new registration. GX
12, at 2. However, on March 5, 2012, following an interview with DEA
Investigators regarding his activities at CPMG, Respondent withdrew
this application. Id. at 2-3.
On March 14, 2013, Respondent submitted a new application, seeking
authority to dispense controlled substances in schedules II through V,
at the registered location of Hometown Urgent Care, 4387 Winston Ave,
Covington, KY. GX 7, at 1. It is this application which is at issue in
this proceeding.
On the application, Respondent was required to answer four
questions, including number two, which asked: ``Has the Respondent ever
surrendered (for cause) or had a federal controlled substance
registration revoked, suspended, restricted or denied, or is any such
action pending?'' Id. at 2. Respondent answered ``N'' for no. Id.
Respondent also holds valid medical licenses in Ohio and Kentucky.
These licenses expire on July 1, 2017 and February 29, 2016,
respectively.\1\
---------------------------------------------------------------------------
\1\ The Government provided copies of online license searches
which show that Respondent is licensed as an osteopathic physician
in Ohio and Kentucky.
---------------------------------------------------------------------------
The Investigation of Respondent
According to a DI, Respondent was previously employed at CPMG from
July 11, 2011 through November 4, 2011. GX 11, at 3 (Declaration of
Diversion Investigator). CPMG was owned by Scott Whitney, and
Respondent was the clinic's sole physician. Id. at 2.
In August 2011, another DI received an anonymous tip alleging that
CPMG was diverting controlled substances. Id. The tipster alleged that
individuals could walk into the clinic without an appointment, could
consult with a doctor in exchange for $250 in cash, that CPMG did not
accept insurance, and that CPMG ``had an in-house pharmacy.'' Id.
Subsequently, the DI determined that Mr. Whitney ``had prior ownership
interests in other pain clinics in the State of Florida'' that had
``dispensed oxycodone'' but had ``since closed.'' Id.
On November 9, 2011, the DI interviewed Respondent. Id. at 3.
Respondent told the DI that at some point prior to starting at CPMG,
Whitney had requested that Respondent pre-sign DEA-222 Forms, which are
required to order schedule II drugs such as oxycodone, see 21 U.S.C.
828(a), ``as a way to start the business.'' Id. Whitney mailed
approximately twenty DEA-222 forms to Respondent, who signed them and
mailed them back to Whitney. Id.
According to the DI, Whitney used at least one of the pre-signed
order forms to place orders for 2,000 du of oxycodone 30 mg and 1,000
oxycodone 10/325 mg from State Pharmaceuticals, Inc. on June 29, 2011.
Id., see also GX 4. The DI also found that Respondent ``authorized []
Whitney to place an order for controlled substances under his DEA . . .
registration without executing a power of attorney for him,'' a
violation of 21 CFR 1305.05(a). Id.
After the conclusion of the interview, the DI asked Respondent if
he would voluntarily surrender his DEA registration. Id. at 3.
Respondent agreed to do so, and executed a Voluntary Surrender Form.
Id.; see also GX 5.
On January 11, 2013, Respondent submitted an application for
renewal of his Ohio medical license. GX 6, at 1. The application
included a question which asked: ``Have you surrendered, consented to
limitation of, or to suspension, reprimand or probation concerning, a
license to practice any healthcare profession or state or federal
privileges to prescribe controlled substances in any jurisdiction other
than Ohio?'' Id. at 3. Respondent answered ``NO.'' Id.
As noted above, on March 14, 2013, Respondent applied for a new
registration. Thereafter, on May 22, 2013, a DI queried the Ohio
Automated Rx Reporting System (OARRS), using Respondent's previously
surrendered DEA registration (BB6473538). GX 12, at 3. The OARRS report
showed that Respondent had issued two controlled substance
prescriptions after he surrendered his registration: 1) on May 5, 2012,
for 60 tablets of Lyrica 75 mg (a schedule V controlled substance) on
May 5, 2012; and 2) on September 12, 2012, for Zutripro 120 ml (a
schedule III cough syrup containing hydrocodone). Id. at 3-4.
The DI then obtained copies of both prescriptions. Id. at 4. The
first prescription, which is dated May 5, 2012, was for 60 capsules of
Lyrica 75 mg, and was printed on a prescription form for Urgent Care of
Fairfield, including its street address. GX 8. The prescription
includes a handwritten signature of ``Art Bell DO'' above ``Art Bell
DO,'' which is printed below the signature line. Id. However, no DEA
number appears on the prescription. Id.
The second prescription, which is dated September 12, 2012, was for
``Bromfed DM 2mg-30mg-10mg/5ml Syrup,'' a non-controlled drug, and was
also on a printed form bearing the name of Urgent Care of Fairfield and
its address. GX 9. However, the drug name is lined-out and the word
``Zutripro'' is handwritten above it. Id. Zutipro is a schedule III
controlled substance which contains hydrocodone. As with the previous
prescription, the signature line contains a handwritten signature of
``Art Bell DO,'' with ``Art Bell DO'' printed below the signature line.
Id. Also written on the prescription is the notation: ``per Katie
Allen.'' Again, no DEA number appears on the prescription.\2\ Id.
According to the DI, on the dates that each prescription was issued,
Respondent was working at
[[Page 50037]]
Urgent Care of Fairfield in Hamilton, Ohio. GX 12, at 4.
---------------------------------------------------------------------------
\2\ GX 8 and GX 9 also include copies of the dispensing labels
for each prescription.
---------------------------------------------------------------------------
Respondent's Statement of Position
In his response to the Order to Show Cause, Respondent stated that
he re-applied for a DEA registration on March 14, 2013, ``not as a
physician seeking authorization to handle controlled substances in
Schedules II through V at a proposed registered address of 4387 Winston
Avenue, Covington, Kentucky [] but to satisfy insurance company
requirements.'' GX 10, at 1 (emphasis in original). He asserted that
``many medical facilities require that their physicians have a DEA
registration, and that ``I hardly ever wrote for any controlled
substances prior to my employment with Care Plus Medical Group.'' Id.
Regarding the allegation that he materially falsified his DEA
application when he provided a ``no'' answer to question two,
Respondent asserted that he provided the answer because ``I voluntarily
surrendered my registration.'' Id. (emphasis in original.) He then
maintained that ``the DEA agent advised me to do so stating that it
most likely would be returned to me within 2-4 weeks. Since I
voluntarily surrendered the registration and no one mentioned (for
cause), I answered the question ``no.'' Id. (emphasis in original).
Respondent added that he ``misunderstood and was completely unaware
that by voluntarily surrendering one's DEA registration equals
voluntarily surrendering (for cause).'' Id. (emphasis in original). He
further stated that ``semantics may have played a part in the confusion
of this situation. Please know that the thought never crossed my mind
to commit a fraudulent act. I apologize for the confusion.'' Id.\3\
---------------------------------------------------------------------------
\3\ As for the false answer he provided on the application for
his Ohio license, Applicant stated that ``the renewal of my
application for an Ohio license was an oversight'' and that he had
re-applied for renewal of his Kentucky and Missouri licenses and
stated on both ``that I had voluntarily surrendered my DEA
registration.'' GX 10, at 2. He wrote that ``I mistakenly thought I
had checked the box that said I had voluntarily surrendered my DEA
registration. . . . Therefore, I checked the box asking `if anything
had changed since my last renewal?' `no'. [sic] I did not intend to
deceive anyone. It was an honest mistake for which I apologize.''
Id.
---------------------------------------------------------------------------
As for the two prescriptions, Respondent denied having issued them.
More specifically, he stated: ``As for the two prescriptions that I
allegedly wrote for Lyrica 75 mg and Zutripro 120ml. I know nothing
about this.'' Id. He then questioned whether there ``was a possibility
that a substitute was given by the nurse without my approval because
insurance would not cover the non-narcotic prescription that I had
originally written?'' Id. He then added that ``I suppose anything is
possible in this circumstance, but rest assured, that I have not
written any prescriptions for controlled substances since the
surrendering of my DEA registration on November 9, 2011.'' Id.
Respondent did admit that he pre-signed 20 DEA-222 forms and that
he sent the forms to Whitney and failed to execute a power of attorney
authorizing Whitney to order the drugs. However, he then contended that
the allegation \4\ that he ``arranged with Mr. Whitney to order
Schedule II controlled substances under [his] previous DEA
registration'' was not a correct statement, because ``Mr. Whitney
arranged this with me--I did not know how to order controlled
substances.'' Id. Continuing, Respondent wrote: ``[a]gain, that action
was pure naivet[eacute] and ignorance of the law on my part'' and
``saying I'm sorry does not even begin to express my remorse . . .
[n]or does it alleviate the feelings of stupidity for my actions
because of the poor judgment that I used on that day.'' Id.
---------------------------------------------------------------------------
\4\ This statement appears as an allegation in the Order to Show
Cause. See GX 1, at 2.
---------------------------------------------------------------------------
Respondent concluded his letter by stating that he ``did not
knowingly tell lies, nor . . . intentionally try to deceive anyone.''
Id. He expressed the hope that his letter ``conveys [his] remorse'' and
stated that he ``would also like to be able to retire in a few years
with my good name intact and above reproach.'' Id.
Discussion
Section 303(f) of the Controlled Substances Act provides that an
application for a practitioner's registration may be denied upon a
determination ``that the issuance of such registration would be
inconsistent with the public interest.'' 21 U.S.C. 823(f). In making
the public interest determination, the CSA requires the consideration
of the following factors:
(1) The recommendation of the appropriate State licensing board or
professional disciplinary authority.
(2) The Applicant's experience in dispensing . . . controlled
substances.
(3) The Applicant's conviction record under Federal or State laws
relating to the manufacture, distribution, or dispensing of controlled
substances.
(4) Compliance with applicable State, Federal, or local laws
relating to controlled substances.
(5) Such other conduct which may threaten the public health and
safety.
Id.
``These factors are . . . considered in the disjunctive.'' Robert
A. Leslie, M.D., 68 FR 15227, 15230 (2003). I ``may rely on any one or
a combination of factors, and may give each factor the weight [I]
deem[] appropriate in determining whether . . . an application for
registration [should be] denied.'' Id. Moreover, while I am required to
consider each of the factors, I ``need not make explicit findings as to
each one.'' MacKay v. DEA, 664 F.3d 808, 816 (10th Cir. 2011) (quoting
Volkman, 567 F.3d 215, 222 (6th Cir. 2009) (quoting Hoxie, 419 F.3d
477, 482 (6th Cir. 2005))).
``In short, this is not a contest in which score is kept; the
Agency is not required to mechanically count up the factors and
determine how many favor the Government and how many favor the
registrant. Rather, it is an inquiry which focuses on protecting the
public interest; what matters is the seriousness of the registrant's
misconduct.'' Jayam Krishna-Iyer, 74 FR 459, 462 (2009).
Also, pursuant to section 304(a)(1), the Attorney General is
authorized to suspend or revoke a registration ``upon a finding that
the registrant . . . has materially falsified any application filed
pursuant to or required by this subchapter.'' 21 U.S.C. 824(a)(1). It
is well established that the various grounds for revocation or
suspension of an existing registration that Congress enumerated in
section 304(a), 21 U.S.C. 824(a), are also properly considered in
deciding whether to grant or deny an application under section 303. See
The Lawsons, Inc., 72 FR 74334, 74337 (2007); Anthony D. Funches, 64 FR
14267, 14268 (1999); Alan R. Schankman, 63 FR 45260 (1998); Kuen H.
Chen, 58 FR 65401, 65402 (1993).
Thus, the allegation that Respondent materially falsified his
application is properly considered in this proceeding. See Samuel S.
Jackson, 72 FR 23848, 23852 (2007). Moreover, just as materially
falsifying an application provides a basis for revoking an existing
registration without proof of any other misconduct, see 21 U.S.C.
824(a)(1), it also provides an independent and adequate ground for
denying an application. The Lawsons, 72 FR at 74338; cf. Bobby Watts,
M.D., 58 FR 46995 (1993).
The Government has ``[t]he burden of proving that the requirements
for . . . registration . . . are not satisfied.'' 21 CFR 1301.44(d).
Having considered all of the public interest factors, as well as the
separate allegation that Respondent materially falsified his
application for a DEA registration, I conclude that the Government has
established a prima facie case to deny his application. While I have
considered Respondent's
[[Page 50038]]
Statement of Position, I do not find his expressions of remorse
persuasive and hold that he has not produced sufficient evidence to
refute the Government's prima facie case. Accordingly, I will order
that his application be denied.
Material Falsification
As found above, on March 4, 2013, Respondent applied for a new
registration and answered ``N'' or no to the question: ``[h]as the
applicant ever surrendered (for cause) or had a federal controlled
substance registration revoked, suspended, restricted or denied, or is
any such action pending?'' Respondent's answer was false because on
November 9, 2011, he voluntarily surrendered his DEA registration
following an interview with a DEA Investigator regarding his activities
at CPMG, during which he admitted to signing schedule II order forms
while failing to execute a power of attorney as required under DEA's
regulation. He then provided those forms to CPMG's owner, thereby by
allowing the latter to order 2,000 du of oxycodone 30 and 1,000 du of
oxycodone 10/325.
This was a violation of DEA regulations and federal law. See 21
U.S.C. 842(a)(5) (``It shall be unlawful for any person . . . to refuse
or negligently fail to make, keep, or furnish any record, report,
notification, declaration, order or order form, statement, invoice, or
information required under this subchapter.''); 21 CFR 1305.04(a)
(``Only persons who are registered with DEA under section 303 of the
Act . . . to handle Schedule I or II controlled substances . . . may
obtain and use DEA From 222 . . . for these substances.''); id. Sec.
1305.05(a) (``A registrant may authorize one or more individuals . . .
to issue orders for Schedule I and II controlled substances on the
registrant's behalf by executing a power of attorney for each such
individual. . . .'').
Respondent nonetheless asserts that he misunderstood the question.
He claims that because he ``voluntarily surrendered'' his
registration'' and ``no one mentioned (for cause),'' he did not believe
that he had surrendered his registration ``for cause.'' However, the
circumstances surrounding the interview during which he surrendered his
registration, coupled with the language of the voluntary surrender form
on which Respondent acknowledged that he was surrendering his
registration ``[i]n view of my alleged failure to comply with the
Federal requirements pertaining to controlled substances'' GX 5, at 1,
are sufficient to support the conclusion that Respondent surrendered
his registration ``for cause.''
I also conclude that Respondent's answer was materially false. As
the Supreme Court has explained, ``[t]he most common formulation'' of
the concept of materiality ``is that a concealment or misrepresentation
is material if it `has a natural tendency to influence, or was capable
of influencing, the decision of' the decisionmaking body to which it
was addressed.'' Kungys v. United States, 485 U.S. 759, 770 (1988)
(quoting Weinstock v. United States, 231 F.2d 699, 701 (D.C. Cir.
1956)) (other citation omitted); see also United States v. Wells, 519
U.S. 482, 489 (1997) (quoting Kungys, 485 U.S. at 770).
``[I]t has never been the test of materiality that the
misrepresentation or concealment would more likely than not have
produced an erroneous decision, or even that it would more likely than
not have triggered an investigation, but rather, whether the
misrepresentation or concealment was predictably capable of affecting,
i.e., had a natural tendency to affect, the official decision.''
Kungys, 485 U.S. at 771. While the evidence must be ``clear,
unequivocal, and convincing,'' the ``ultimate finding of materiality
turns on an interpretation of the substantive law.'' Id. at 772 (int.
quotations and citations omitted).
Notwithstanding that the Agency did not grant his application,
Respondent's false answer to question two was clearly ``capable of
affecting'' the decision of whether to grant his application because he
surrendered his registration in response to allegations that he
violated DEA regulations, and under the public interest standard, the
Agency is required to consider the Applicant's ``[c]ompliance with
applicable State, Federal, or local laws relating to controlled
substances.'' 21 U.S.C. 823(f)(4). Accordingly, I conclude that
Respondent materially falsified his March 2013 application for
registration.
In his statement, Respondent contends that ``semantics may have
played a part in the confusion of this situation. Please know that the
thought never crossed my mind to commit a fraudulent act. I apologize
for the confusion.'' GX 10, at 1.
Respondent's explanation is not persuasive. Here, the evidence also
shows that when Respondent applied for his Ohio medical license, the
State's application contained the following question: ``Have you
surrendered, consented to limitation of, or to suspension, reprimand or
probation concerning . . . state or federal privileges to prescribe
controlled substances in any jurisdiction other than Ohio?'' GX 6, at
3. Respondent, however, answered ``NO.'' Id. Notably, in contrast to
the question on the DEA application, the Ohio question did not ask
whether he surrendered ``for cause'' and thus presented no issue of--in
Respondent's view--semantics. Further, Respondent does not claim that
he was confused by the question.\5\ Id. Yet Respondent still provided a
false answer to the Ohio question. Thus, I reject his claim of
confusion and conclude that his false answer on the Ohio application is
probative of his intent in answering the DEA question and that his
intent was fraudulent. Cf. Fed. R. Evid. R. 404(b)(2).
---------------------------------------------------------------------------
\5\ Rather, Respondent asserts that his answer on the Ohio
medical license application ``was an oversight,'' that he
``mistakenly thought I had checked the box that said I had
voluntarily surrendered my DEA registration,'' and that ``I checked
the box asking `if anything had changed since my last renewal?'
`no.' '' GX 10, at 2. However, Respondent filed his Ohio medical
license application on January 11, 2013, and according to the Web
site of the State Medical Board, ``Doctors of Osteopathic Medicine
[DOs] are required to renew their licenses biennially in order to
maintain an active certificate to practice.'' See https://www.med.ohio.gov/RenewalCME/DoctorofOstepathicMedicine(DO).aspx.
As found above, Respondent surrendered his DEA registration on
November 9, 2011, and given that his Ohio license was good for two
years, I conclude that his previous Ohio application was filed
before he surrendered his DEA registration. Thus, at the time he
filed his Ohio medical license application, something ``had changed
since [his] last renewal.'' GX 10, at 2. Moreover, the Ohio
application clearly instructed: ``Please review all information you
have provided. Click on the `Review' button to change any
information given. . . .'' GX 6, at 2. The form also included the
following statements: ``I understand that submitting a false,
fraudulent, or forged statement or document or omitting a material
fact in obtaining licensure may be grounds for disciplinary action
against my license'' and ``Under penalty of law, I hereby swear or
affirm that the information I have provided in the application is
complete and correct, and that I have complied with all criteria for
applying on line.'' Id. at 6.
---------------------------------------------------------------------------
This conclusion finds further support in the circumstances
surrounding the March 5, 2012 interview, which resulted in his
withdrawal of the January 5, 2012 application. While the Government did
not submit any evidence as to whether Respondent truthfully answered
Question Two on this application, a DEA Investigator provided a sworn
statement that on March 5, 2012, he interviewed Respondent regarding
his activities at CPMG.\6\ See GX 12, at 2. According to the DI, ``[a]t
the conclusion of the interview, DEA investigators informed
[Respondent's] legal counsel that [he] could face criminal charges
based on his previous handling of controlled substances on behalf of
CPMG.'' Id. at 2-3. Thereafter,
[[Page 50039]]
Respondent consulted with his attorney and decided to withdraw his
application. Id. at 3. Given that the March 5, 2012 interview involved
the same matters as had been discussed at the time Respondent
surrendered his registration and that he had been threatened with
criminal prosecution, Respondent cannot credibly argue that, at the
time he submitted the March 2013 application, he remained confused as
to whether he had previously surrendered the registration ``for
cause.''
---------------------------------------------------------------------------
\6\ Agency records, of which I take official notice, see 21 CFR
1316.59(e), show that Applicant also answered ``No'' to Liability
Question Two on his January 2012 application. There is, however, no
evidence that his response was specifically addressed by the
investigating DI at the time.
---------------------------------------------------------------------------
I therefore conclude that substantial evidence supports findings
that Respondent materially falsified his application for March 2013
application for registration when he failed to disclose that he had
surrendered his DEA registration ``for cause,'' and that he did so
intentionally. See GX 10, GX 12 at 2-3. I further conclude that these
findings support the denial of Respondent's application.
The Public Interest Analysis
The Government also argues that Respondent's application should be
denied on the separate ground that his registration is ``inconsistent
with the public interest.'' 21 U.S.C. 823(f). More specifically, the
Government argues that factors two (experience in dispensing), four
(compliance with applicable laws related to controlled substances) and
five (other conduct which may threaten public health and safety),
support the denial of his application.\7\ Government's Request for
Final Agency Action, at 10.
---------------------------------------------------------------------------
\7\ I acknowledge that Applicant remains licensed in Kentucky,
the State in which he seeks registration, and therefore, he meets
the CSA's prerequisite for holding a practitioner's registration in
that State. See 21 U.S.C. 823(f) (``The Attorney General shall
register practitioners . . . to dispense . . . controlled substances
. . . if the applicant is authorized to dispense . . . controlled
substances under the laws of the State in which he practices.'');
see also id. Sec. 802(21) (``The term `practitioner' means a
physician . . . or other persons licensed, registered, or otherwise
permitted, by the United States or the jurisdiction in which he
practices . . . to distribute, dispense, . . . [or] administer . . .
a controlled substance.'').
However, the possession of state authority ``is not dispositive
of the public interest inquiry.'' George Mathew, 75 FR 66138, 66145
(2010), pet. for rev. denied, Mathew v. DEA, 472 Fed. Appx. 453 (9th
Cir. 2012); see also Patrick W. Stodola, 74 FR 20727, 20730 n.16
(2009). As the Agency has long held, ``the Controlled Substances Act
requires that the Administrator . . . make an independent
determination [from that made by state officials] as to whether the
granting of controlled substance privileges would be in the public
interest.'' Mortimer Levin, 57 FR 8680, 8681 (1992). Accordingly,
this factor is not dispositive either for, or against, the granting
of Respondent's application. Paul Weir Battershell, 76 FR 44359,
44366 (2011) (citing Edmund Chein, 72 FR 6580, 6590 (2007), pet. for
rev. denied, Chein v. DEA, 533 F.3d 828 (D.C. Cir. 2008)).
As for factor three, there is no evidence that Applicant has
been convicted of an offense ``relating to the manufacture,
distribution or dispensing of controlled substances.'' 21 U.S.C.
823(f)(3). However, there are a number of reasons why even a person
who has engaged in misconduct may never have been convicted of an
offense under this factor, let alone prosecuted for one. Dewey C.
MacKay, 75 FR 49956, 49973 (2010), pet. for rev. denied MacKay v.
DEA, 664 F.3d 808 (10th Cir. 2011). The Agency has therefore held
that ``the absence of such a conviction is of considerably less
consequence in the public interest inquiry'' and is therefore not
dispositive. Id.
---------------------------------------------------------------------------
With regard to factors two and four, the Government alleges that
Respondent issued two controlled-substance prescriptions after he
surrendered his registration. In his written statement, Respondent
denies any knowledge of both prescriptions, and posits ``that a
substitute was given by a nurse without [his] approval because
insurance would not cover the non-narcotic prescription that [he] had
originally written?'' GX 10, at 2.
Having reviewed the signatures on the prescriptions with the other
documents in the record which indisputably contain Respondent's
signature (i.e., his written statement of position, the voluntary
surrender form, and the DEA Form 222), I conclude that Respondent
signed both prescriptions. See United States v. Clifford, 704 F.2d 86,
90 n.5 (3d Cir. 1983) (``[A] jury can compare a known handwriting
sample with another sample to determine if the handwriting in the
latter sample is genuine. The jury can make that comparison without the
benefit of expert witnesses.'') (citations omitted); see also 28 U.S.C.
1731 (``The admitted or proved handwriting of any person shall be
admissible, for purposes of comparison, to determine genuineness of
other handwriting attributed to such person.'').
Notwithstanding that Respondent did not include a DEA number on the
prescription, I find that Respondent unlawfully issued the May 5, 2012
prescription for Lyrica. See 21 U.S.C. 841(a)(1) (``Except as
authorized by this subchapter, it shall be unlawful for any person
knowingly or intentionally . . . to . . . dispense . . . a controlled
substance.''); id. Sec. 822(a)(2) (Every person who dispenses . . .
shall obtain from the Attorney General a registration issued in
accordance with the rules and regulations promulgated by him.''); 21
CFR 1306.03(a)(2) (``A prescription for a controlled substance may be
issued only by an individual practitioner who is . . . [e]ither
registered or exempted from registration. . . .''); Cf. id. Sec.
843(a)(2) (``It shall be unlawful for any person knowing or
intentionally . . . to use in the course of the . . . dispensing of a
controlled substance . . . a registration number which is fictitious,
revoked, suspended, [or] expired. . . .'').
However, I do not find the evidence sufficient to sustain the
allegation as to the September 12, 2012 prescription. As the evidence
shows, the prescription was originally issued for Bromfed DM (a non-
narcotic), but was then changed to Zutripro, a schedule III controlled
substance, and bears the handwritten notation ``per Katie Allen.'' The
Government offered no further evidence regarding the circumstances
surrounding the change in the prescription. It did not explain who Ms.
Katie Allen is and where she was working on September 12, 2012. Nor did
it offer any evidence that it interviewed the pharmacist who filled the
prescription, the patient, or Ms. Allen.
As found above, Respondent also admitted that he pre-signed twenty
schedule II order forms and that he mailed them to Whitney, so that
Whitney could order controlled substances for his pain clinic and
``start the business,'' which Whitney then used to order oxycodone.
Respondent violated federal law and Agency regulations because while he
clearly authorized Whitney to order the drugs, he failed to execute a
power of attorney for him. See 21 U.S.C. 842(a)(5); 21 CFR 1305.04(a);
id. Sec. 1305.05(a).\8\
---------------------------------------------------------------------------
\8\ Of further note, Whitney could not have obtained the order
forms without Respondent having provided him with his DEA
Registration number, which is pre-printed on the forms when issued
by DEA. See GX 4; see also 21 CFR 1305.04(a). However, the Agency
has repeatedly held that a registrant is strictly liable for any
misconduct engaged in by a person to whom a registrant entrusts his
registration. See Satinder Dang, 76 FR 51424, 51429 (2011); Rosemary
Jacinta Lewis, 72 FR 4035, 4041 (2007). The evidence offered by the
Government as to whether Whitney and Respondent were diverting
controlled substances at CPMG does not, however, create more than a
suspicion.
---------------------------------------------------------------------------
Respondent admitted to these violations. GX 10, at 2. However, he
then stated that he ``did not know how to order controlled substances''
and that ``that action was pure naivet[eacute] and ignorance of the law
on my part.'' \9\ GX 10, at 2. This is not a particularly persuasive
explanation for one who seeks a DEA registration.
---------------------------------------------------------------------------
\9\ It is well settled that ``ignorance of the law or a mistake
of law is no defense.'' Cheek v. United States, 498 U.S. 192, 199
(1991). Moreover, the principle ``applies whether the law be a
statute or a duly promulgated and published regulation.'' United
States v. International Minerals & Chemical Corp., 402 U.S. 558, 563
(1971).
---------------------------------------------------------------------------
I therefore conclude that the evidence with respect to factors two
and four supports the conclusion that issuing Respondent a new
registration ``would be inconsistent with the public interest.'' 21
U.S.C. 823(f).
[[Page 50040]]
Factor Five
The Government further argues that Respondent committed actionable
misconduct under factor five when he failed to disclose the surrender
of his DEA registration on his application to the Ohio Medical Board.
Request for Final Agency Action, at 11. In support of its contention,
the Government cites David A. Hoxie, M.D., 69 FR 51477, 51478 (2004),
for the proposition that providing false answers on a state
professional license application ``demonstrate[s] questionable
candor.'' Id. (citing Bernard C. Musselman, M.D., 64 FR 55965 (1999)).
It also cites Leonard E. Reeves, III, 63 FR 44471, 44784 (1998), which
ordered a stayed revocation of the physician's DEA registration
relying, in part, on a state board's denial of the physician's
application for a medical license based on the physician's ``total lack
of truthful, accurate and complete answers on his written application
for licensure.'' \10\
---------------------------------------------------------------------------
\10\ The physician was not, however, registered in the State
which found that he had submitted a false application for a second
medical license.
---------------------------------------------------------------------------
Undoubtedly, providing a materially false answer to a question on a
state medical license application is probative evidence of whether a
registrant or applicant demonstrates ``questionable candor.'' However,
here, in contrast to Reeves, there has been no adjudication by the
State of Ohio and Respondent retains a valid osteopathic license in
that State. Thus, the question remains as to whether this Agency should
be adjudicating this allegation in the first instance, especially
where, as here, Respondent is neither registered in Ohio nor seeks
registration in that State.
To be sure, Hoxie went beyond Reeves by holding that the
physician's falsifications of his medical license applications were
actionable under factor five even in the absence of a state board
finding. Hoxie, however, preceded the Supreme Court's decision in
Gonzales v. Oregon, 546 U.S. 243 (2006). Therein, the Supreme Court
explained that the CSA ``manifests no intent to regulate the practice
of medicine generally'' and that ``[t]he structure and operation of the
CSA presume and rely upon a functioning medical profession regulated
under the States' police powers.'' Id. at 270.
While the Government contends that Respondent's false statement on
his Ohio medical license application can be considered as a separate
act of actionable misconduct under factor five, it offers no
explanation as to why it is consistent with Gonzales, that DEA, rather
than the Ohio Medical Board, should be the first body to adjudicate the
issue. Nor does the Government offer any explanation as to why the Ohio
Board is incapable of enforcing its own laws. Finally, the Government
does not even cite the applicable provision of Ohio law, let alone
explain whether there is a materiality requirement under Ohio law, and
if so, what the standard is under Ohio law.
While the Government's position would be stronger if Respondent was
registered in Ohio--on the theory that the falsification of his state
application resulted in the State granting him the osteopathic license
necessary to obtain his DEA registration,\11\ see 21 U.S.C. 823(f)--
Respondent is neither registered, nor seeking registration, in Ohio.
Thus, in the absence of a state board finding, I decline to follow
Hoxie and do not consider Respondent's falsification of his Ohio
application other than for the limited purpose of evaluating his claim
that he was confused by the wording on his DEA application.\12\
---------------------------------------------------------------------------
\11\ It seems unlikely that a physician would falsify his state
medical license application but then truthfully disclose a sanction
against his federal registration on his DEA application.
\12\ Notably, Hoxie does not cite Reeves, but rather Musselman,
as authority for the proposition. See 69 FR at 51479. While
Musselman discusses the factual findings of a state board proceeding
which was based, in part, on an allegation that the physician had
falsified a state license application, the state board did not find
the allegation proved, and in discussing factor five, the Agency's
decision discusses only the physician's falsification of his DEA
application. See 64 FR at 55967. Thus, Musselman clearly does not
support Hoxie.
---------------------------------------------------------------------------
Summary of the Government's Prima Facie Case
As found above, Respondent intentionally and materially falsified
his March 14, 2013 application for a DEA registration. This finding
alone provides an adequate basis to deny his application. 21 U.S.C.
824(a)(1) and 843(a)(4)(A).
The evidence also shows that Respondent violated DEA regulations
when he provided schedule II order forms to Mr. Whitney, CPMG's owner,
and authorized him to order oxycodone without having executed a power
of attorney as required by 21 CFR 1305.05(a). Finally, the evidence
also shows that Respondent issued a prescription for Lyrica, a schedule
V controlled substance, when he was no longer registered, and thus
violated 21 U.S.C. 841(a)(1) and 822(a)(2). I therefore find that the
Government's evidence under factors two and four is sufficient to
conclude that the Government has met its prima facie burden on the
issue of whether the issuance of a registration ``would be inconsistent
with the public interest.'' 21 U.S.C. 823(f).
Sanction
Where, as here, the Government has established grounds to deny an
application, Respondent must then ``present[] sufficient mitigating
evidence'' to show why he can be entrusted with a new registration.
Samuel S. Jackson, 72 FR 23848, 23853 (2007) (quoting Leo R. Miller, 53
FR 21931, 21932 (1988)). ```Moreover, because `past performance is the
best predictor of future performance,' ALRA Labs, Inc. v. DEA, 54 F.3d
450, 452 (7th Cir. 1995), [DEA] has repeatedly held that where [an
applicant] has committed acts inconsistent with the public interest,
the [applicant] must accept responsibility for [his] actions and
demonstrate that [he] will not engage in future misconduct.'' Jayam
Krishna-Iyer, 74 FR 459, 463 (2009) (citing Medicine Shoppe, 73 FR 364,
387 (2008)); see also Jackson, 72 FR at 23853; John H. Kennedy, 71 FR
35705, 35709 (2006); Cuong Tron Tran, 63 FR 64280, 64283 (1998); Prince
George Daniels, 60 FR 62884, 62887 (1995).\13\
---------------------------------------------------------------------------
\13\ This rule also applies to other grounds that support the
denial of an application, such as where the Government has proven
that an applicant materially falsified his application. See Jackson,
72 FR, at 23853.
---------------------------------------------------------------------------
While an applicant must accept responsibility for his misconduct
and demonstrate that he will not engage in future misconduct in order
to establish that its registration is consistent with the public
interest, DEA has repeatedly held that these are not the only factors
that are relevant in determining the appropriate sanction. See, e.g.,
Joseph Gaudio, 74 FR 10083, 10094 (2009); Southwood Pharmaceuticals,
Inc., 72 FR 36487, 36504 (2007). Obviously, the egregiousness and
extent of a registrant's misconduct are significant factors in
determining the appropriate sanction. See Jacobo Dreszer, 76 FR 19386,
19387-88 (2011) (explaining that a respondent can ``argue that even
though the Government has made out a prima facie case, his conduct was
not so egregious as to warrant revocation''); Paul H. Volkman, 73 FR
30630, 30644 (2008); see also Paul Weir Battershell, 76 FR 44359, 44369
(2010) (imposing six-month suspension, noting that the evidence was not
limited to security and recordkeeping violations found at first
inspection and ``manifested a disturbing pattern of indifference on the
part of [r]espondent to his obligations as a registrant''); Gregory D.
Owens, 74 FR 36751, 36757 n.22 (2009). So too, the Agency can consider
the need to deter similar acts, both with respect to the
[[Page 50041]]
respondent in a particular case and the community of registrants. See
Gaudio, 74 FR at 10095 (quoting Southwood, 71 FR at 36503). Cf.
McCarthy v. SEC, 406 F.3d 179, 188-89 (2d Cir. 2005) (upholding SEC's
express adoption of ``deterrence, both specific and general, as a
component in analyzing the remedial efficacy of sanctions'').
Having reviewed Respondent's Statement of Position, I conclude that
he has failed to produce sufficient evidence to show why he should be
entrusted with a new registration. His acceptance of responsibility is
equivocal at best, as while he appears to acknowledge his wrongdoing
with respect to his having provided the Schedule II order forms to Mr.
Whitney, his explanation for why he materially falsified his DEA
application is clearly disingenuous. So too, is his assertion that he
``did not knowingly tell lies, nor . . . intentionally try to deceive
anyone.'' Because Respondent committed intentional misconduct when he
materially falsified his application, I find his misconduct to be
egregious.\14\ Accordingly, his failure to accept responsibility for
this misconduct is reason alone to conclude that he cannot be entrusted
with a new registration.\15\ Moreover, the Agency has a manifest
interest in deterring misconduct on the part of others who may
contemplate materially falsifying their applications for registration.
Accordingly, I conclude that denial of his application is necessary to
protect the public interest.
---------------------------------------------------------------------------
\14\ Having found that Respondent's material falsification of
his application is egregious and that he has not accepted
responsibility for the violation, I need not decide whether the
other proven violations are sufficiently egregious to support the
denial of the application.
\15\ As to the violation in authorizing Whitney to order
schedule II drugs, Respondent stated that this was the result of
``pure naivet[eacute] and ignorance of the law on my part.''
However, Respondent has offered no evidence of remedial actions he
has taken to demonstrate that he is now familiar with the laws and
regulations applicable to the lawful dispensing of controlled
substances.
---------------------------------------------------------------------------
Order
Pursuant to the authority vested in me by 21 U.S.C. 823(f), as well
as 28 CFR 0.100(b), I order that the application of Arthur H. Bell,
D.O., for a DEA Certificate of Registration as a practitioner be, and
it hereby is, denied. This Order is effective immediately.
Dated: August 10, 2015.
Chuck Rosenberg,
Acting Administrator.
[FR Doc. 2015-20353 Filed 8-17-15; 8:45 am]
BILLING CODE 4410-09-P